國家衛生研究院 NHRI:Item 3990099045/14468

NHRI > National Center for Geriatrics and Welfare Research > Chen-Yu Wang > Periodical Articles > Item 3990099045/14468

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14468

Title:	Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson’s disease when considering the coexisting effects of diabetes mellitus
Authors:	Chen, HC;Wang, CY;Chen, HH;Liou, HH
Contributors:	National Center for Geriatrics and Welfare Research
Abstract:	Objective This study aims to investigate the cost-effectiveness of the add-on exenatide to conventional pharmacotherapy in patients with Parkinson’s disease (PD) when considering the coexistence of diabetes mellitus (DM). Methods We used the Keelung and Community-based Integrated Screening databases to understand the medical utilisation in the Hoehn and Yahr stages of patients with PD. A Markov model with 1-year cycle length and 50-year time horizon was used to assess the cost-effectiveness of add-on exenatide to conventional pharmacotherapy compared to conventional pharmacotherapy alone. All costs were adjusted to the value of the new Taiwanese dollar (NT$) as of the year 2020. One-way sensitivity and probability analyses were performed to test the robustness of the results. Results From a societal perspective, the add-on exenatide brought an average of 0.39 quality-adjusted life years (QALYs) gained, and a cost increment of NT$104,744 per person in a 50-year horizon compared to conventional pharmacotherapy. The incremental cost-effectiveness ratio (ICER) was NT$268,333 per QALY gained. As the ICER was less than the gross domestic product per capita (NT$839,558), the add-on exenatide was considered to be very cost-effective in the two models, according to the World Health Organization recommendation. Add-on exenatide had a 96.9% probability of being cost-effective in patients with PD, and a 100% probability of being cost-effective in patients with PD and DM. Conclusion Add-on exenatide is cost-effective in PD combined with DM. Considering that DM may be a risk factor for neurodegenerative diseases, exenatide provides both clinical benefits and cost-effectiveness when considering both PD and DM.
Date:	2022-08-11
Relation:	PLoS ONE. 2022 Aug 11;17(8):Article number e0269006.
Link to:	http://dx.doi.org/10.1371/journal.pone.0269006
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1932-6203&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000947311000005
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85135907064
Appears in Collections:	[Chen-Yu Wang] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85135907064.pdf		1219Kb	Adobe PDF	163	View/Open

Loading...